How does Wegovy compare to Saxenda?
Wegovy and Saxenda are both GLP-1 receptor agonist injections prescribed under NICE guidance within specialist weight management services in the UK. Wegovy contains semaglutide and is administered once weekly, while Saxenda contains liraglutide and requires daily injections. Clinical trials show that patients using Wegovy lose on average 15.8% of their body weight after 68 weeks, compared with 6.4% average loss with Saxenda over a similar period. Both treatments must be used alongside a reduced-calorie diet, increased physical activity, and specialist support to achieve optimal results. Common side effects for both include gastrointestinal symptoms such as nausea and vomiting, but the less frequent dosing of Wegovy may improve convenience and adherence.[1][2][3][4][5]
- Both are GLP-1 receptor agonists prescribed under NICE guidance in specialist services.[1][2]
- Wegovy (semaglutide) is injected weekly; Saxenda (liraglutide) is injected daily.[1][3]
- Average weight loss is about 15.8% with Wegovy versus 6.4% with Saxenda after roughly 68 weeks.[5]
- Both require concurrent lifestyle changes—diet, exercise—and specialist referral for initiation and monitoring.[1][2][4]
- Side effects are similar (mostly nausea and GI upset), though Wegovy’s weekly dosing may enhance convenience.[1][3]